ConvEyXO is a pioneering therapeutic company dedicated to unlocking the transformative power of exosomes. Established in 2019 by a team of seasoned experts in cell therapy, our mission is to democratize access to exosome-based treatments, making them more accessible and affordable for all. Through strategic collaborations, joint ventures, acquisitions, and licensing agreements, we have cultivated a robust intellectual property portfolio of Deep Technologies.

In line with our commitment to therapeutic innovation, we’ve developed a comprehensive therapeutic portfolio focused on fibrosis and chronic inflammatory disorders. Among these, osteoarthritis (OA) has been selected as our inaugural proof-of-concept disease. However, our ambitions extend far beyond, with ongoing developments in oncology, heart failure, NASH, and neurodegenerative diseases.

At ConvEyXO, we focus on bolstering our capabilities in the realm of therapeutic innovation. By integrating breakthrough manufacturing techniques (Exo-Harvest) and advanced loading technologies (XomeXBio), we have developed a unique platform poised to revolutionize the production of exosomes on a large scale. This platform enables the efficient delivery of bioactive compounds in a targeted manner, ensuring maximum therapeutic efficacy.

Our commitment to advancing the field of therapeutics drives every aspect of our work, from research and development to commercialization. ConvEyXO is at the forefront of harnessing the therapeutic potential of exosomes to improve health outcomes and enhance the quality of life for patients worldwide.


We were founded and are led by an ambitious team with decades of expertise in pharmaceutical development, biologics and manufacturing. Many of our team have worked together for years and have a strong track-record in drug approvals and commercial success.

Jean-Paul Prieels, CEO

PhD, served as a Senior Vice President of Research and Development at GSK Biologicals

Jean Small, CTO

Served as Vice-President, Head of New Product Development at GSK Vaccines.

Marcelle Van Mechelen, CSO

PhD immunologist, served as Vice President of Research and Preclinical Development at GSK

Frédéric Tonglet, Deputy CEO

Commercial Engineer, with a proven track record of success in the finance and biotech sectors over the last 25 years